Please try another search
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company. The Company is focused on developing and commercializing its immunomodulator platform technology. The Company’s core technology platform is based on Cowpea mosaic virus (CPMV), which is non-infectious to humans or other animals but upon intra-tumoral administration, elicits an innate immune response resulting in potent antitumor activity against the primary and distant tumor sites. The Company’s lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as CPMV. The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). MIE-101 is used for the treatment of many different types of cancer.
Name | Age | Since | Title |
---|---|---|---|
Steven W. King | 59 | 2020 | Chairman of the Board, President & CEO |
Gloria H. Felcyn | 76 | 2002 | Independent Director |
Robert L. Garnick | 73 | 2020 | Independent Director |
Robert A. Baffi | 68 | 2021 | Independent Director |
Carlton M. Johnson | 64 | 2001 | Director |
Paul J. Lytle | 56 | 2020 | Executive VP, CFO, Secretary & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review